Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival

Clinical Cancer Research

Volumn 10, Issue 19, 2004, Pages 6559-6566

  Rosen, Daniel G ^a   Wang, Lin ^a,c   Jain, Ajay N ^b   Lu, Karen H ^a   Luo, Robert Z ^a   Yu, Yinhua ^a   Liu, Jinsong ^a   Bast Jr , Robert C ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PROTEIN P21;

ADULT; AGED; ARHI GENE; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTADENOMA; DNA MICROARRAY; DOWN REGULATION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPEROXIDASE STAINING; IN SITU HYBRIDIZATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; OVARY CYST; OVARY FOLLICLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE INJURY; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RHO GTP-BINDING PROTEINS; RNA, MESSENGER; TIME FACTORS;

EID: 5144231704     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0698     Document Type: Article

References (28)

1. Fujita M, Enomoto T, Murata Y. Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes. Mol Cell Endocrinol 2003;202(1-2):97-9.
2. Patton SE, Martin ML, Nelsen LL, et al. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res 1998;58(10):2253-9.
3. Kitayama H, Sugimoto Y, Matsuzaki T, et al. A ras-related gene with transformation suppressor activity. Cell 1989;56(1):77-84.
4. Yu Y, Xu F, Peng H, et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 1999;96(1):214-9.
5. Peng H, Xu F, Pershad R, et al. ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. Int J Cancer 2000;86(5):690-4.
6. Wang L, Hoque A, Luo RZ, et al. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res 2003;9(10 Pt 1):3660-6.
7. Yuan J, Luo RZ, Fujii S, et al. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res 2003;63(14):4174-80.
8. Fujii S, Luo RZ, Yuan J, et al. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet 2003;12(15):1791-800.
9. Luo RZ, Peng H, Xu F, et al. Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. Biochim Biophys Acta 2001;1519(3):216-22.
10. Bao JJ, Le XF, Wang RY, et al. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res 2002;62(24):7264-72.
11. Luo RZ, Fang X, Marquez R, et al. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 2003;22(19):2897-909.
12. Benda JA, Zaino R, eds. GOG pathology manual. Buffalo, NY: Gynecological Oncology Group; 1994.
13. Staging announcement: FIGO cancer committee. Gynecol Oncol 1986;25:383-5.
14. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002;7 Suppl 5:20-8.
15. Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996;7(4):361-4.
16. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170(4):974-9;discussion 9-80.
17. Hoskins WJ. Epithelial ovarian carcinoma: principles of primary surgery. Gynecol Oncol 1994;55(3 Pt 2):S91-6.
18. Mills GB, Fang X, Lu Y, et al. Specific keynote: molecular therapeutics in ovarian cancer. Gynecol Oncol 2003;88 (1 Pt 2):S88-92; discussion S3-6.
19. Noda A, Ning Y, Venable SF, et al. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994;211(1):90-8.
20. Parker SB, Eichele G, Zhang P, et al. p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. Science (Wash. DC) 1995;267(5200):1024-7.
21. Halevy O, Novitch BG, Spicer DB, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (Wash. DC) 1995;267(5200):1018-21.
22. Li R, Waga S, Hannon GJ, et al. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature (Lond.) 1994;371(6497):534-7.
23. Waga S, Hannon GJ, Beach D, et al. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature (Lond.) 1994;369(6481):574-8.
24. Michieli P, Chedid M, Lin D, et al. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994;54(13):3391-5.
25. Schmider A, Gee C, Friedmann W, et al. p21 (WAF1/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma. Gynecol Oncol 2000;77(2): 237-42.
26. Anttila MA, Kosma VM, Hongxiu J, et al. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer 1999;79(11-12):1870-8.
27. Bast RC, Jr., Boyer CM, Jacobs I, et al. Cell growth regulation in epithelial ovarian cancer. Cancer (Phila.) 1993;71(4 Suppl):1597-601.
28. Berchuck A. Biomarkers in the ovary. J Cell Biochem Suppl 1995; 23:223-6.